3 completed, 3 unknown, 1 recruiting, 1 terminated. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 3, Unknown 3, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Unknown 2 |
Follow Hepatitis, Autoimmune: new trials by email Literature Review of Hepatitis, Autoimmune trials Research Report on Hepatitis, Autoimmune
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SIPLIZUMAB in AILD and LT Patients Siplizumab - Autoimmune Liver Disease, Liver Transplant Disorder | Phase 1 | Recruiting | Elizabeth C. Verna | 8 | 2024-09-11 | 2025-11-24 |
| Relative Bioavailability Study of HR19042 in Healthy Subjects HR19042 Capsule, Tarpeyo®, Budenofalk® - Primary IgA Nephropathy; Autoimmune Hepatitis | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 18 | 2023-12-27 | 2025-04-22 |
| A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule JKB-122 in capsule or tablet form - Autoimmune Hepatitis | Phase 1 | Unknown | TaiwanJ Pharmaceuticals Co., Ltd | 8 | 2020-08-01 | 2020-07-15 |
| Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis Orencia® (Abatacept) - Autoimmune Hepatitis | Phase 1 | Terminated | Stuart Knechtle, M.D. | 1 | 2020-03-09 | 2021-11-29 |
| Selected Mesenchymal Stromal Cells to Reduce Inflammation in Patients With PSC and AIH Orbcel-C - Cholangitis, Sclerosing, Hepatitis, Autoimmune | Phase 1 / Phase 2 | Unknown | University of Birmingham | 18 | 2018-12-07 | 2024-07-11 |
| sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS sPIF, Placebo - Autoimmune Hepatitis | Phase 1 | Completed | Christopher O'Brien, MD | 36 | 2014-11-14 | 2019-11-20 |
| Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis conventional plus UC-MSC treatment, Conventional plus placebo treatment - Autoimmune Hepatitis | Phase 1 / Phase 2 | Unknown | Beijing 302 Hospital | 100 | 2011-10-01 | 2013-05-31 |
| Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis ursodeoxycholic acid (UDCA) - Primary Sclerosing Cholangitis | Phase 1 | Completed | University of Tennessee | 27 | 2010-10-01 | 2017-10-26 |
Cholangitis, Sclerosing (3) · Cholangitis (1) · End Stage Liver Disease (1) · Fibrosis (1) · Glomerulonephritis, IGA (1) · Hepatitis (1) · Liver Cirrhosis (1) · Liver Diseases (1)
Autoimmune Diseases (8) · Digestive System Diseases (8) · Hepatitis, Chronic (8) · Immune System Diseases (8) · Hepatitis (7) · Liver Diseases (7) · Bile Duct Diseases (3) · Biliary Tract Diseases (3) · Cholangitis (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Fibrosis (1) · Glomerulonephritis (1)
Abatacept (1) · Budesonide (1) · Capsules (1) · Congresses as Topic (1) · JKB-122 (1) · Ringer's Lactate (1) · Ursodeoxycholic Acid (1) · preimplantation factor, synthetic (1) · siplizumab (1)
Beijing 302 Hospital (1) · Christopher O'Brien, MD (1) · Elizabeth C. Verna (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Stuart Knechtle, M.D. (1) · TaiwanJ Pharmaceuticals Co., Ltd (1) · University of Birmingham (1) · University of Tennessee (1)
United States (4) · China (2) · United Kingdom (1)
Benjamin Shneider, M.D. (1) · Christopher B. O'Brien, MD (1) · Dennis D Black, M.D. (1) · Elizabeth Verna, MD (1) · Fu-Sheng Wang, professor (1) · Phillip N Newsome, Prof (1) · Stuart Knechtle, MD (1)